Potential of oligonucleotide- and protein/peptide-based therapeutics in the management of toxicant/stressor-induced diseases

Exposure to toxicants/stressors has been linked to the development of many human diseases. They could affect various cellular components, such as DNA, proteins, lipids, and non-coding RNAs (ncRNA), thereby triggering various cellular pathways, particularly oxidative stress, inflammatory responses, a...

Full description

Saved in:
Bibliographic Details
Published in:Naunyn-Schmiedeberg's archives of pharmacology 2024-03, Vol.397 (3), p.1275-1310
Main Authors: Sadeghian, Issa, Akbarpour, Mina, Chafjiri, Fatemeh Mohammad Alizadeh, Chafjiri, Pegah Mohammad Alizadeh, Heidari, Reza, Morowvat, Mohammad Hossein, Sadeghian, Razieh, Raee, Mohammad Javad, Negahdaripour, Manica
Format: Article
Language:English
Subjects:
Apoptosis
Biomedical and Life Sciences
Biomedicine
Humans
Inflammation
Intermediates
Lipids
MicroRNAs
MicroRNAs - genetics
miRNA
Neurosciences
Non-coding RNA
Oligonucleotides
Oligonucleotides - pharmacology
Oligonucleotides - therapeutic use
Oxidative stress
Peptides
Peptides - therapeutic use
Pharmacology/Toxicology
Proteins
Review
RNA, Small Interfering
RNA, Untranslated - genetics
RNA, Untranslated - metabolism
siRNA
Toxicants
Toxicity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Exposure to toxicants/stressors has been linked to the development of many human diseases. They could affect various cellular components, such as DNA, proteins, lipids, and non-coding RNAs (ncRNA), thereby triggering various cellular pathways, particularly oxidative stress, inflammatory responses, and apoptosis, which can contribute to pathophysiological states. Accordingly, modulation of these pathways has been the focus of numerous investigations for managing related diseases. The involvement of various ncRNAs, such as small interfering RNA (siRNA), microRNAs (miRNA), and long non-coding RNAs (lncRNA), as well as various proteins and peptides in mediating these pathways, provides many target sites for pharmaceutical intervention. In this regard, various oligonucleotide- and protein/peptide-based therapies have been developed to treat toxicity-induced diseases, which have shown promising results in vitro and in vivo. This comprehensive review provides information about various aspects of toxicity-related diseases including their causing factors, main underlying mechanisms and intermediates, and their roles in pathophysiological states. Particularly, it highlights the principles and mechanisms of oligonucleotide- and protein/peptide-based therapies in the treatment of toxicity-related diseases. Furthermore, various issues of oligonucleotides and proteins/peptides for clinical usage and potential solutions are discussed.
ISSN:0028-1298
1432-1912
DOI:10.1007/s00210-023-02683-3